

Testicular Cancer Epidemiology Forecast 2025-2034

Market Report | 2025-05-12 | 150 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2699.00
- Five User License \$3739.00
- Corporate License \$4929.00

Report description:

Testicular Cancer Epidemiology Forecast 2025-2034

According to the American Cancer Society, approximately 9,729 new cases of testicular cancer are expected to be identified in the United States in 2025. Additionally, the disease is projected to cause nearly 600 deaths in the same year. The typical age at which individuals are diagnosed with testicular cancer is around 33 years.

Testicular Cancer Epidemiology Forecast Report Coverage

The Testicular Cancer Epidemiology Forecast Report 2025-2034 by Expert Market Research delivers a comprehensive analysis of the condition's prevalence and associated demographic factors. It projects future incidence and prevalence trends across diverse population groups, considering key variables such as age, gender, and testicular cancer type. The report highlights changes in prevalence over time and offers data-driven forecasts based on influencing factors. Additionally, it provides an in-depth overview of the disease, along with historical and projected epidemiological data for eight key markets: the United States, United Kingdom, France, Italy, Spain, Germany, Japan, and India.

Testicular Cancer: Disease Overview

Testicular cancer is a malignant condition that originates in the testicles, the male reproductive glands located within the scrotum. It primarily affects younger and middle-aged men, with most diagnoses occurring between the ages of 15 and 44. The disease often begins in the germ cells, which are responsible for producing sperm, and is broadly classified into seminomas and non-seminomas, each differing in growth rate and treatment response. Early symptoms may include a painless lump, swelling, or discomfort in the testicle. Testicular cancer is highly treatable, especially when detected early, with common interventions including surgery, radiation therapy, and chemotherapy depending on the stage and type.

Epidemiology Overview

The epidemiology section on testicular cancer provides detailed insights into the patient population from historical data to present-day figures, along with forecasts across the eight major markets. Expert Market Research analyses multiple studies to outline both existing and anticipated trends. The report highlights diagnosed case numbers, segmented by factors such as age

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

groups and patient demographics.

- According to the American Cancer Society, approximately 1 in 250 males will be diagnosed with testicular cancer in their lifetime.
- Research indicates the average age of diagnosis is 33, with 8% of cases found in men over 55 and 6% in children and teenagers.
- Cancer Research UK reported around 2,376 testicular cancer cases between 2017 and 2019 in the UK, with roughly 65 deaths.
- Among racial groups, white men in the United States show the highest incidence of the disease.

Testicular Cancer: Treatment Overview

Testicular Cancer: Burden Analysis

Treatment for testicular cancer typically involves a multidisciplinary approach, including surgery, chemotherapy, radiotherapy, and active surveillance depending on the cancer type and stage. The majority of patients are diagnosed early, leading to high survival rates. Seminomas and non-seminomas, the two main types of testicular cancer, respond well to treatment. Physicians determine treatment based on tumour markers, imaging results, and pathology. Advancements in targeted therapies and fertility preservation methods are improving outcomes and quality of life. Below are key treatment options commonly used for testicular cancer:

1. Orchiectomy

Orchiectomy is the primary surgical treatment for testicular cancer. It involves the removal of one or both testicles through an incision in the groin. This procedure is often the first step after diagnosis and provides tissue for further pathological analysis. Orchiectomy helps prevent cancer spread and is usually followed by additional therapies depending on the tumor stage and type. The surgery is typically straightforward and recovery time is short. Fertility and hormone levels can be affected, so patients may consider sperm banking and testosterone monitoring post-surgery.

2. Chemotherapy

Chemotherapy uses powerful drugs to eliminate cancer cells, particularly in advanced or metastatic testicular cancer. It is especially effective for non-seminomatous germ cell tumors. Commonly used regimens include BEP (Bleomycin, Etoposide, and Cisplatin), usually administered over several cycles. Chemotherapy is often recommended after orchiectomy if cancer has spread to lymph nodes or distant organs. While highly effective, it can cause temporary side effects such as nausea, fatigue, hair loss, and increased infection risk. Long-term effects like infertility or cardiovascular issues are monitored in survivorship care plans.

3. Radiotherapy

Radiotherapy is most commonly used to treat seminomas, which are highly sensitive to radiation. It involves directing targeted radiation beams at lymph nodes, usually in the abdominal or pelvic region, to destroy residual cancer cells. This treatment is generally used after surgery if there's a high risk of recurrence. Radiotherapy is less frequently used for non-seminomas due to lower effectiveness. Side effects may include fatigue, skin irritation, and digestive issues. Advances in imaging and technology have improved the precision of radiation delivery, minimizing damage to healthy tissues.

4. Retroperitoneal Lymph Node Dissection (RPLND)

RPLND is a complex surgical procedure performed to remove lymph nodes in the abdomen where testicular cancer may spread, especially in cases involving non-seminomatous germ cell tumors. This procedure is often done after chemotherapy if residual masses remain or in early-stage cancer with a high risk of metastasis. RPLND requires expert surgical skill and may result in temporary digestive issues or loss of ejaculation due to nerve damage, though nerve-sparing techniques can help preserve

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

function. It offers a potential cure when cancer is confined to the lymph nodes.

5. Active Surveillance

Active surveillance is recommended for patients with early-stage testicular cancer, particularly those with low-risk seminomas or non-seminomas. This approach involves regular follow-ups, including physical exams, blood tests, and imaging, to monitor for recurrence without immediate treatment. It avoids overtreatment and preserves quality of life while maintaining high survival outcomes. If any signs of recurrence are detected, curative treatment is initiated promptly. This strategy is gaining popularity due to the excellent prognosis of testicular cancer and the desire to reduce long-term treatment-related side effects.

Key Epidemiology Trends

Testicular cancer continues to show distinctive epidemiological patterns that reflect both biological factors and evolving healthcare practices. While it remains a relatively rare form of cancer, accounting for a small percentage of male cancers globally, recent trends highlight significant developments in its incidence, demographics, risk patterns, and outcomes. These shifts are crucial for improving early detection strategies, tailoring public health initiatives, and optimizing treatment approaches.

1. Rising Incidence in Developed Regions

One of the most notable trends is the increasing incidence of testicular cancer in developed countries, particularly in Europe, North America, and Oceania. Although the underlying reasons are not fully understood, environmental and lifestyle factors, including exposure to endocrine-disrupting chemicals, delayed parenthood, and reduced physical activity, are believed to contribute. The increase is especially prominent among young and middle-aged men, which is prompting further investigation into genetic and environmental interactions. Improved diagnostic awareness and access to healthcare in these regions may also account for part of the rise.

2. Age-Related Diagnosis Patterns

Testicular cancer remains a disease that predominantly affects younger males, with the highest prevalence observed in individuals aged 15 to 40. However, recent years have shown subtle shifts in age-related diagnosis. While the median age remains consistent, there has been a gradual increase in cases among older men, particularly those over 55. This trend is drawing attention to the need for more inclusive awareness campaigns, which traditionally focus on younger populations. Age-specific changes in testicular function or prolonged exposure to risk factors might be contributing to these emerging patterns.

3. Racial and Ethnic Disparities

Epidemiological studies have shown that testicular cancer has higher incidence rates among Caucasian men compared to other racial or ethnic groups. However, recent data indicate a gradual narrowing of this gap, with incidence increasing among Hispanic and African American populations in some regions. This could reflect changes in environmental exposures or improvements in healthcare access and cancer reporting. These disparities underscore the importance of developing culturally relevant awareness and screening initiatives to ensure early diagnosis and effective treatment across all demographic groups.

4. Improved Survival and Early Detection

Survival rates for testicular cancer continue to improve, largely due to earlier detection and advances in treatment. Public awareness campaigns and the availability of high-quality diagnostic imaging have led to an increase in the detection of early-stage tumours. Consequently, more patients are receiving timely and effective interventions. The continued evolution of surgical techniques, chemotherapeutic regimens, and post-treatment surveillance strategies has significantly reduced mortality, especially in high-income nations. The focus now extends to survivorship care, including fertility preservation and management of long-term side effects.

5. Increased Incidence of Germ Cell Tumours

There has been a documented rise in germ cell tumours, the most common histological subtype of testicular cancer. These

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

tumours, which include both seminomas and non-seminomas, are believed to have origins in foetal development but typically manifest in adolescence or early adulthood. The increasing incidence suggests a complex interplay between genetic susceptibility and prenatal or early-life environmental factors. Research is ongoing to understand these triggers, and the trend reinforces the need for longitudinal studies and targeted preventive strategies focused on reproductive health and environmental risk exposures.

Analysis By Region

The epidemiology of testicular cancer varies across countries and regions due to differences in healthcare infrastructure, socioeconomic factors, cultural attitudes towards pain, and access to pain management therapies. Understanding these variations is essential for developing targeted interventions and improving patient outcomes.

Key regions include:

- [] The United States
- [] Germany
- [] France
- [] Italy
- [] Spain
- [] The United Kingdom
- [] Japan
- [] India

These regions exhibit distinct epidemiological trends, reflecting the unique challenges and opportunities within their healthcare systems.

The prevalence of testicular cancer differs notably across countries, influenced by genetic predispositions (including family history and conditions like cryptorchidism), lifestyle habits, dietary patterns, environmental influences, and disparities in healthcare access. In the United States, it is estimated that approximately 10,000 men are diagnosed with testicular cancer each year.

Key Questions Answered

- [] What are the primary genetic and environmental risk factors associated with the incidence of testicular cancer across different populations?
- [] How does the age distribution of testicular cancer diagnoses vary across global regions?
- [] What trends have emerged over the past decade in testicular cancer incidence and mortality rates?
- [] How do racial and ethnic differences influence testicular cancer prevalence and survival outcomes?
- [] What role does early detection play in improving survival rates for testicular cancer patients?
- [] How has the prevalence of testicular cancer changed in high-income versus low-income countries?
- [] What is the impact of cryptorchidism on the lifetime risk of developing testicular cancer?
- [] How do lifestyle factors such as smoking, physical activity, or diet correlate with testicular cancer risk?
- [] What is the average latency period between exposure to risk factors and onset of testicular cancer symptoms?
- [] How accurate and complete are cancer registries in capturing the true burden of testicular cancer globally?

Scope of the Report

- [] The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

and classification/types of testicular cancer based on several factors.

-□The testicular cancer epidemiology forecast report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)

-□The report helps to identify the patient population, the unmet needs of testicular cancer are highlighted along with an assessment of the disease's risk and burden.

Table of Contents:

1 Preface

1.1 Introduction

1.2 Objectives of the Study

1.3 Research Methodology and Assumptions

2 Executive Summary

3 Testicular Cancer Market Overview - 8 MM

3.1 Testicular Cancer Market Historical Value (2018-2024)

3.2 Testicular Cancer Market Forecast Value (2025-2034)

4 Testicular Cancer Epidemiology Overview - 8 MM

4.1 Testicular Cancer Epidemiology Scenario (2018-2024)

4.2 Testicular Cancer Epidemiology Forecast

5 Disease Overview

5.1 Signs and Symptoms

5.2 Causes

5.3 Risk Factors

5.4 Guidelines and Stages

5.5 Pathophysiology

5.6 Screening and Diagnosis

5.7 Types of Testicular Cancer

6 Patient Profile

6.1 Patient Profile Overview

6.2 Patient Psychology and Emotional Impact Factors

7 Epidemiology Scenario and Forecast - 8 MM

7.1 Key Findings

7.2 Assumptions and Rationale

7.3 Testicular Cancer Epidemiology Scenario in 8MM (2018-2034)

8 Epidemiology Scenario and Forecast: United States

8.1 Testicular Cancer Epidemiology Scenario and Forecast in the United States (2018-2034)

9 Epidemiology Scenario and Forecast: United Kingdom

9.1 Testicular Cancer Epidemiology Scenario and Forecast in United Kingdom (2018-2034)

10 Epidemiology Scenario and Forecast: Germany

10.1 Testicular Cancer Epidemiology Scenario and Forecast in Germany (2018-2034)

11 Epidemiology Scenario and Forecast: France

11.1 Testicular Cancer Epidemiology Scenario and Forecast in France

12 Epidemiology Scenario and Forecast: Italy

12.1 Testicular Cancer Epidemiology Scenario and Forecast in Italy (2018-2034)

13 Epidemiology Scenario and Forecast: Spain

13.1 Testicular Cancer Epidemiology Scenario and Forecast in Spain (2018-2034)

14 Epidemiology Scenario and Forecast: Japan

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1 Testicular Cancer Epidemiology Scenario and Forecast in Japan (2018-2034)
- 15 Epidemiology Scenario and Forecast: India
- 15.1 Testicular Cancer Epidemiology Scenario and Forecast in India (2018-2034)
- 16 Patient Journey
- 17 Treatment Challenges and Unmet Needs
- 18 Key Opinion Leaders (KOL) Insights

Testicular Cancer Epidemiology Forecast 2025-2034

Market Report | 2025-05-12 | 150 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2699.00
	Five User License	\$3739.00
	Corporate License	\$4929.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com